[Disclosure] Alteogen(196170) Holds its 16th Annual General Meeting of Shareholders; All Agendas Approved Including Financial Statements and Director Appointments

Source Fact: Financial Supervisory Service DART / 2024-03-26

Disclosure Type: Results of Annual General Meeting of Shareholders

💡 3-Second Summary

At its Annual General Meeting held on March 26, Alteogen approved its 16th fiscal year financial statements with clean audit opinions and passed all six agendas, including the appointments of Inside Director Tae-Yeon Jeon and Outside Director Sang-Cheol Lee.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Hosting Entity: Alteogen Co., Ltd. (Ticker: 196170)
• Date of Shareholders’ Meeting: March 26, 2024
• Approval of 16th Fiscal Year Financial Statements (Unit: KRW Million):
  • Separate (Non-consolidated): Total Assets: 203,942 / Total Liabilities: 17,415 / Total Equity: 186,527 / Capital Stock: 26,506 / Revenue: 83,478 / Operating Income: -904 / Net Income: 4,871 (Earnings per Share: KRW 94)
  • Consolidated: Total Assets: 256,100 / Total Liabilities: 108,258 / Total Equity: 147,842 / Capital Stock: 26,506 / Revenue: 96,523 / Operating Income: -9,737 / Net Loss: -3,582 (Earnings per Share: KRW -65)
  • External Auditor’s Opinion: ‘Unqualified (Clean)’ for both separate and consolidated statements.
• Dividend Resolution: No cash, property, or stock dividends declared ( – ).
• Appointment of Directors and Auditor (3-year term each):
  • Inside Director: Tae-Yeon Jeon (Newly appointed; Current Vice President & CAO of Alteogen, U.S. Patent Attorney).
  • Outside Directors: In-Young Ko (Re-appointed; Current Outside Director, Professor at Kangwon National University), Sang-Cheol Lee (Newly appointed; Former Director of National Agenda Research Division at Korea Research Foundation).
  • Standing Auditor: Byung-Gyu Lee (Re-appointed; Current Standing Auditor of Alteogen, Former Branch Manager at Hana Bank).
  • Board Composition Post-Meeting: 5 Directors in total, including 2 Outside Directors (Ratio of Outside Directors: 40%), and 1 Standing Auditor.
• Other Approved Agendas: Approval of compensation limits for directors and the auditor, and approval of stock option grants.

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing details the final voting results of the corporate annual general meeting, which is a mandatory statutory requirement. The successful execution and resolution of a shareholders’ meeting do not induce immediate shifts in corporate fundamental, pipeline values, or commercial licensing deals, and should be interpreted as a routine administrative event wrapping up the prior fiscal year.

From a financial perspective, market participants should observe the variance between separate and consolidated earnings metrics. While the parent company recorded a net profit of KRW 4.8B on a separate basis, it printed an operating loss of KRW 9.7B and a net loss of KRW 3.5B on a consolidated basis due to subsidiary accounts. This disclosure does not explain the specific reasons for the earnings fluctuations; however, securing ‘unqualified’ opinions across both financial sheets effectively resolves potential accounting risks. Strategically, the appointment of Dr. Tae-Yeon Jeon, a U.S. patent attorney, as an inside director may bring a potential impact on strengthening the company’s global intellectual property defenses and cross-border out-licensing structures. Investors are advised to track how this reorganized board executes upcoming clinical trials and asset commercialization over a long-term horizon.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s regular annual general meeting concluded smoothly with zero unexpected variables. The structural takeaways from this filing are the finalization of the fiscal audited books and the enhancement of board-level expertise. With audit risk minimized by receiving clean opinions, the data confirms a consolidated net loss of KRW 3.5B, driven by R&D spending from consolidated subsidiaries despite separate profit lines. The most notable corporate governance update is the addition of Vice President Tae-Yeon Jeon to the inside board. Holding a Ph.D. in biochemistry and legal credentials as a U.S. patent attorney, his presence gives Alteogen an optimized executive setup to protect its subcutaneous transformation platforms and navigate international licensing deals. With the administrative milestones checked off, investors should focus on verified subsequent updates regarding clinical developments rather than speculating on unconfirmed forum rumors.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.